On May 5, 2020, Medigen Vaccine Biologics Corp. (MVC) announced a global commercial license agreement with National Institutes of Health (NIH). Within the agreement, NIH grants MVC the rights to obtain the original biomaterials of recombinant spike protein, the antibodies for analysis, the technology platform and the patents related to the platform and the vaccine candidate.

MVC has the right to develop, and commercialize worldwide. At the beginning of the COVID-19 outbreak, NIH designed this recombinant spike protein based on the previous platform of recombinant spike protein. MVC has conducted preclinical immunogenicity studies in early March and has completed preliminary testing and evaluation.

MVC is a cell-based biopharmaceutical company focusing on the development and production of vaccines and biologics. MVC’s business partners include US NIH, US CDC, WHO/UCAB, Taiwan CDC, and Taiwan National Health Research Institute. MVC’s pipeline includes enterovirus A71 vaccine, dengue vaccine, influenza quadrivalent vaccine which all entered late clinical stage.